DirectorVern Davenport is a partner at NovaQuest Capital Management with extensive executive experience in building and transforming healthcare technology and services companies. He is responsible for transaction origination and execution, portfolio company value creation initiatives, and investment policy. Before joining NovaQuest Capital, Vern was CEO and board member at Medfusion. He was instrumental in the carve-out of the company from Intuit and returning its core portal solution to a market leadership position. Prior to Medfusion, Vern was chairman and CEO of Medquist, a leader in transcription services before and after the privatization of the company. There, he facilitated a transformation of the business through the acquisition of a speech technology company, rebranding the company M*Modal and leading the take-private process. Vern’s previous experience also includes his time as president, Allscripts; CEO, Misys Healthcare; GM & EVP, Kodak Health Group (now Carestream Health); and, executive leadership roles at Siemens and Shared Medical Systems. He started his career at IBM where he spent 11 years in sales, sales leadership, and executive management positions. Vern holds a B.S.B.A and an M.B.A from East Carolina University, and is on the East Carolina Board of Trustees and WakeMed Health and Hospitals Board.
DirectorConor Green is a principal at TT Capital Partners (TTCP) and works on sourcing and leading investments in healthcare services and healthcare information technology companies. During his career he has evaluated and worked with many different businesses, as an operator, advisor, and an investor. At TTCP, he works closely with a number of portfolio companies to help maximize their potential. Prior to joining TripleTree, Conor served in a product strategy role at athenahealth, a publicly-traded provider of web-based software and services to physicians. Prior to that, he worked in M&A and strategy roles within Reed Elsevier, but primarily with Elsevier, the company’s science publishing division. Conor began his career at L.E.K. Consulting, where he completed engagements in the M&A due diligence practice as well as a number of longer-term projects for healthcare IT and life sciences clients. Conor earned a B.A. in Politics from Princeton University and an M.B.A. from the Stanford Graduate School of Business.
Jacqueline Kosecoff, PhD
DirectorDr. Jacqueline (Jackie) Kosecoff works in private equity to identify, select, mentor and manage health services and IT companies. She is managing partner at Moriah Partners, LLC, and senior advisor at Warburg Pincus. Previously, she served as a senior executive with UnitedHealth Group-PacifiCare where she was chief executive officer of OptumRx. Jackie was founder, president and chief operating officer of Protocare, and earlier, served as professor of Medicine and Public Health at the University of California, Los Angeles. She holds a B.A. from the University of California, Los Angeles, an M.S. in Applied Mathematics from Brown University, and a doctorate from the University of California, Los Angeles.
David Patrick Nixon
CEO and DirectorDavid brings 25 years of healthcare experience and a record of entrepreneurial leadership to his role as CEO of InformedDNA. Since joining InformedDNA in 2007, David has led the company’s transformation from the premier national genetic counseling provider network to becoming the first mover in the rapidly growing field of genetic testing utilization management (GTUM). InformedDNA is now the leading Genetic Benefits Management™ organization; working with national and regional health plans as well as hospitals and health systems throughout the US to ensure patients have convenient access to genetic services and providers are able to work with genetic specialists for genetic testing decision support.
DirectorDawn Owens is president of TripleTree Holdings, with broad responsibility across TripleTree’s investment banking and TT Capital Partner’s private equity services. Dawn brings extensive healthcare experience to the firm, including a national reputation as a dynamic leader who has lead companies through various stages of growth, from turnaround to high growth. In her role, Dawn engages industry stakeholders, from innovative and earlier-stage companies to Fortune 200 leaders, to understand the market forces driving disruption and the potential for continued innovation in healthcare. Prior to joining the firm, Dawn served as CEO of OptumHealth, a multi-line UnitedHealth Group company. Under her leadership, OptumHealth became one of the nation’s largest and most respected health and well-being companies. Dawn’s prior roles include Chief Marketing Officer of Ingenix (now OptumInsight) and President of Uniprise (now a part of UnitedHealthcare). She started her healthcare career at Aetna Health Plans. Dawn earned a B.A. from Grove City College.
DirectorMichael Sorensen is a partner at NovaQuest Capital Management with extensive investment experience. He is responsible for transaction origination and execution, portfolio company value creation initiatives, investment policy, and investor relations. He is also member of the Private Equity investment committee. Prior to NovaQuest Capital, Michael was a director in BlackRock’s private equity group. In that role, he was responsible for making investment decisions in a wide variety of geographies and industries, including healthcare, technology, and consumer/retail, among others. Prior to BlackRock, Michael worked at Sorenson Capital (no familial relation), a mid-market private equity firm based in Salt Lake City. Similar to his current role, he analyzed private companies in a wide range of industry sub-sectors and geographies. Michael also worked as a consultant for L.E.K. Consulting, where he worked closely with clients’ senior management on projects that included asset optimization, strategic planning, and customer segmentation, primarily in the healthcare and media industries. Michael holds a B.S. in Economics from Brigham Young University, an M.P.A. from Harvard University, and an M.B.A. from the Wharton School at the University of Pennsylvania.
DirectorEric Steager is a staff vice president of corporate venture capital at Anthem, Inc., the largest Blue Cross Blue Shield plan, leading its strategic equity investment initiatives. Prior to Anthem, he co-managed and helped start the corporate venture arm of Independence Blue Cross (IBC) focusing on the identification, analysis and execution of strategic equity investments, as well as mergers and acquisitions. Eric has also been an Adjunct Professor of Finance and Entrepreneurship at both Drexel University and Temple University. Prior to joining IBC, he spent several years at both a private investment firm focused on venture capital and private equity investments, and Safeguard Scientifics, a publicly traded venture capital firm. Eric’s early career included founding a private investment fund focused on acquiring middle market manufacturing companies in the Midwestern United States, and healthcare investment banking at Houlihan Lokey and Ernst & Young. He holds an M.B.A. from the University of Chicago, Booth School of Business, and a bachelor’s degree from Drexel University.
Rebecca Sutphen, MD, FACMGG
Co-Founder and Chief Medical OfficerDr. Rebecca Sutphen has broad clinical and molecular genetics expertise in conditions affecting both adults and children. She is among the few individuals certified by the American Board of Medical Genetics in clinical genetics, molecular genetics and cytogenetics. Rebecca previously served as director of Clinical Genetics for Moffitt Cancer Center & Research Institute. She is also an experienced researcher in genomics and proteomics and has been funded by the American Cancer Society, the Department of Defense, and the National Institutes of Health. Rebecca has received numerous awards and honors, including being named to "Florida's Super Doctors," "America's Top Doctors for Cancer," and "Best Doctors in America," as well as the National Comprehensive Cancer Network Guidelines Panel, which sets the standard-of-care for genetics and familial cancer screening.